News & Updates

COVID-19 patients remain on the recovery phase 6 months after hospital admission, with persistent fatigue but improving lung function and quality of life, according to a study.

Adolescents and adults with severe uncontrolled asthma while on inhaled corticosteroids (ICS) had greater responses to the human monoclonal antibody tezepelumab than placebo, according to prespecified exploratory results of the phase III NAVIGATOR trial.

Chronic obstructive pulmonary disease (COPD) is associated with an earlier diagnosis of lung cancer, according to a cross-sectional, real-world study.

Older adults have weaker antibody responses to two doses of COVID-19 vaccines [ie, mRNA-based BNT162b2 vaccine and inactivated CZ02 vaccine] vs younger individuals, but a booster dose mounts SARS-CoV-2 neutralization activities to a high level, according to data presented at AIM 2022.

Oral dexamethasone proved more effective than oral prednisolone for the management of acute exacerbation of mild-to-moderate asthma in children, a study suggests.

A real-world study during Hong Kong’s Omicron BA.2 wave showed that both molnupiravir and nirmatrelvir/ritonavir effectively lowered the risks of disease progression and all-cause mortality in hospitalized COVID-19 patients not requiring oxygen supplementation on admission. However, mortality risk reduction was larger with nirmatrelvir/ritonavir vs molnupiravir.

In rheumatoid arthritis-related interstitial lung disease (RA-ILD), change over time in the levels of serum proteins, such as matrix metallopeptidase 13 (MMP13) and C-X-C motif ligand chemokine 11 (CXCL11), predict clinical outcomes, a recent study has found. The same is true for baseline clinical factors such as patient age and rheumatoid factor.

Device-guided breathing (DGB), as facilitated by the RESPeRATE device, appears to reduce test anxiety and can boost subsequent test performance among students, according to a recent study.